**COMPANY REGISTRATION NUMBER : 7225131** 

# **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE UNAUDITED FINANCIAL STATEMENTS FOR YEAR ENDED 30 JUNE 2021** 

**Charity Number : 1136067** 


Edmund Carr LLP Chartered Accountants 146 New London Road 

Chelmsford Essex CM2 OAW 



## **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE** 

## **FINANCIAL STATEMENTS** 

## **YEAR ENDED 30 JUNE 2021** 

|**CONTENTS**|**PAGE**|
|---|---|
|Company information|**1**|
|Trustees' annual report|**2**|
|Independent Examiner's report to the Trustees|**10**|
|Statement of financial activities|**11**|
|Balance sheet|**12**|
|Notes to the financial statements|**13**|





## **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE** 

## **COMPANY INFORMATION** 

## **YEAR ENDED 30 JUNE 2021** 

**Charity Number** 1136067 **Company Number** 7225131 **Registered Office** 35-43 Lincoln's Inn Fields London WC2A 3PE 

## **THE TRUSTEES** 

The Trustees of the charity are also the directors of the charity. 

The Trustees who served the charity during the year were as follows: 

Mr Hassan Malik President Mr Zaed Hamady Vice President Mr John Whiting Honorary Treasurer Mr Michael Shackcloth EJSO Representative Professor Michael Douek Honorary Secretary Professor Jim Khan Meeting Secretary Professor Jayant Vaidya Deputy Meeting Secretary Mr Edmund Leung Professor Derek Manas Professor Richard Shaw Mr Aaron Quyn (Appointed 23/11/2020) Mr Anant Desai (Appointed 23/11/2020) Mr Riccardo Bonomi (Resigned 23/11/2020) 

-1- 



## **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE TRUSTEES' ANNUAL REPORT** 

## **YEAR ENDED 30 JUNE 2021** 

The Trustees have pleasure in presenting their report and the unaudited financial statements for the charity for the period ended 30th June 2021. The Trustees of the charity as shown on page 1 are also the directors of the charity. 

## **Objectives and Activities** 

The Charity’s objectives are: 

_**To advance the science, practice, and art of surgical oncology**_ for the benefit of patients with cancer; and to _**promote research, training, and education in surgical oncology**_ for the benefit of the public, patients and the medical community, and to disseminate the useful results of that research appropriately. 

The Association seeks to act as an umbrella organisation for those working in all surgical cancer specialties and cancer research. _In addition, the Society focuses on innovation in cancer care and support for future workforce training and development._ The Trustees pay due regard to the Charity Commission’s guidance on public benefit when deciding what activities the Charity should undertake. 

## _**Portfolio of Awards**_ 

The Association takes great pride in its **portfolio of awards** to encourage our junior colleagues and to support their interest in the field of surgical oncology, its research and care of cancer patients. The Society continues awarding the following prizes at its annual scientific meeting: 

- **Alan Edwards Memorial Prize** is awarded to the best poster presentation. 

- **Ronald Raven Presentation Prize** is awarded to the best oral paper presentation. 

- **BASO~ACS Presentation Prize** , formerly known as BJS Prize, is awarded to the best oral paper presentation. Due to the change of structure, the British Journal of Surgery Society (BJSS) discontinued to support this prize. In 2019, BASO Council agreed to sponsor this prize to ensure continuity to the BJS Paper Presentation Prize awarded at the BASO Meeting. 

- **BASO Trainees (poster/oral presentation) Prize** is awarded to the best poster and oral paper presentations at the BASO Trainees Meeting. In addition, each year, BASO also presents the BASO Trainees Prizes in support of our trainee colleagues presenting papers at different surgical societies such as the Association of Surgeons in Training (ASiT), the Society for Cardiothoracic Surgery (SCTS), and the Association of Surgeons of Great Britain & Ireland (ASGBI). 

To expand its commitment to all cancer-related professionals, BASO announced the following two new prizes at the 2019 BASO Annual Scientific Meeting: 

- **BASO Trainees Audit/QIP Prize** to support and encourage trainees, those involved with audit and quality improvement with a view of improving care to patients, in particular, cancer patients. 

- **BASO Multidisciplinary Prize** to recognise the work done by our Non-Medical Professional colleagues in supporting cancer patients. This unique award is designed to highlight any research, audit, quality improvement, health service provision/development, cancer patient pathway study, cancer survivorship study. 

## _**BASO Grants**_ 

BASO is expanding its portfolio of research grants to support cancer research and treatment. 

**BASO Raven Travelling Fellowship** - (formerly known as Ronald Raven Travelling Fellowship) was endowed in 1993 by the Ronald Raven Trustees in memory of the Founder of the Association’s Ronald W. Raven. BASO Continues to fund and award this fellowship, which has now increased to £3,000, each year to aspiring trainees to support them to expand their skills and experience in the surgical cancer treatment. 

-2- 



**BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE** 

## **TRUSTEES' ANNUAL REPORT (continued)** 

## **YEAR ENDED 30 JUNE 2021** 

**BASO (NIHR) Research Project Grant** - BASO continues to be a non-commercial partner with the National Institute of Health Research (NIHR) and runs a successful annual research project grant scheme to assist surgeons in undertaking research projects related to surgically linked cancer care. This grant is open for discrete projects and a study awarded this grant is automatically eligible for consideration for the Clinical Research Network Support, thereby, is considered for being a portfolio study. 

## _**Endorsement of Regional Events**_ 

The Association aspires to engage with oncologists and Societies on the regional level. Via its network of Regional Representatives, BASO had been supporting various regional and national meetings.  However, the participation has been limited during this accounting year due to the COVID. 

## _**Engagement with Medical Students**_ 

In the spirit of encouraging the future generation of surgical oncologists, the Association has opened its Trainees membership to Foundation Year Trainees and Medical Students those wishing to pursue surgical oncology. BASO aims to offer support with their surgical career by providing skills courses, mentoring sessions, and guiding surgical portfolio via our wealth of regional representatives. 

The Society is actively engaging with undergraduate Medical Societies by sponsoring their annual meeting with BASO Prize and sponsored lectures. 

## _**BASO Trainees Group**_ 

BASO Trainees group continued growing their outlook and strengthened their links with trainees groups from across Europe. Through these collaborations, we encouraged trainees in tenets of research and clinical excellence in surgical oncology through the sponsored prizes at national specialty meetings. Our Trainees group continues to focus on research, academic training, and fellowships. 

## _**BASO @ the ACCEA Committee**_ 

In addition to its role within education and training, BASO is one of the selected few organisations that play a significant role in the assessment of and nominations for the Clinical Excellence Awards. BASO Council continues to sit on the ACCEA Award Committee and offers consultation to the ACCEA Focus Group. 

## _**BASO’s contribution to NICE consultations and Cancer CRGs**_ 

The Society continues to make its mark and offers expert advice on numerous site-specific Surgical Cancer consultations as requested by NICE. Our Council members sit on various Cancer CRG’s, offering expert advice. 

**Overall, the Society is maintaining healthy relations with all the surgical societies, the Royal Colleges, and exploring collaborative working opportunities.** 

## **Achievements and Performance** 

The Society has been proactive in dealing with the COVID-19 pandemic and its challenges have demonstrated the need for an umbrella organisation to speak with one voice. BASO is growing its membership, maintained steady finances and delivered a successful virtual meetings this year. 

## _**COVID –19**_ 

BASO is actively engaged in supporting our members and front-line clinicians to continue providing essential cancer surgery.  BASO had issued the ‘Strategy for Cancer Surgery sustainability and recovery in the COVID19 pandemic’ guidance to support its members. 

-3- 



## **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE** 

## **TRUSTEES' ANNUAL REPORT (continued)** 

## **YEAR ENDED 30 JUNE 2021** 

An edited version of BASO's guidance was produced as a joint letter on behalf of ESSO and BASO to the Editor of the EJSO with a vision to expand our message to our colleagues in other European Countries. BASO’s guidance was well received by our members and fellow colleagues, and was supported by numerous national and international surgical societies. 

BASO also contributed to the NHS England document, 'Maintenance of Essential Cancer surgery for adults during the COVID-19 emergency'.   BASO’s recommendations, particularly, on screening, self-isolation of patients, and shielding of patients were included in the NHSE document. 

BASO is also actively engaged with the CovidSurg-Cancer Study and is one of the key sponsors of this study. CovidSurg-Cancer is an international cohort study, designed by the team in Birmingham to assess the safety of surgery for all types of cancer during COVID-19 pandemic and the impact of pandemic in cancer delay and treatment pathways.  BASO, as the non-commercial NIHR partner, is one of the Societies that offers a small surgical research grant to this study which would entitle it to be listed on the NIHR Portfolio. 

The COVID-19 Pandemic has put immense strain on our healthcare system, however, our Trustees also believe that it has also led to innovation in a short period of time, and hope to continue providing support to our members and cancer community. 

## _**BASO Annual Meeting**_ 

2020 had been a challenging year and to support the ongoing education needs of its members and surgical community during these difficult times, BASO delivered its first virtual Annual Meeting. The meeting was themed on Education” and was delivered under the leadership of our President Mr Hassan Malik and Professor Michael Douek as the Meeting Secretary. 

The meeting was facilitated by an array of international speakers and panellists, all esteemed surgeons in the field of surgical oncology and had an attendance of 170 delegates. The feedback received from delegates and speakers was extremely positive, both about the content of the programme and the virtual organisation. The meeting generated a small profit. 

94 abstracts were presented under oral or poster presentation sessions, and 8 prizes were awarded for best abstract presentations. It was however decided by the BASO Council to postpone the prestigious BASO Plenary Awards until 2021, to ensure that these awards were presented in person. 

The key highlights of the programme were: 

- Communication and Leadership skills in light of Covid-19. 

- Tips on training opportunities due to Covid to help minimising effects of training loss. 

- Debate Session: “This house believes cancer surgery should be done in specialised cancer hospitals”. 

- • Informal “Breakfast session with BASO Council”. 

- Breast cancer IORT – where are we now? - session facilitated by international panellists. 

- Global Surgery - the Covid effect facilitated by Prof Jiong Wu, Prof Richard Sullivan, Miss Rachel Hargest. 

- Medico-legal issues in Covid times, presented an engaging presentation by Mr Robert Wheeler and Professor Peter Sagar. 

- Virtual presentations of oral and poster abstracts. 

- Live Q&A opportunities for delegates and panels. 

The Association aspires to continue building on the success of this programme and making BASO meetings financially sustainable. 

-4- 



## **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE** 

## **TRUSTEES' ANNUAL REPORT (continued)** 

## **YEAR ENDED 30 JUNE 2021** 

## _**European Journal of Surgical Oncology**_ 

**The EJSO** , co-owned by BASO and the ESSO continues to go from strength to strength with a rise in the quality of submission and article downloads.  The 2020 impact factor were released earlier in June.  The EJSO impact factor has increased to 4.424 from 3.959 from last year.  (Follow link for more details: - https://journalinsights.elsevier.com/journals/0748 7983/impact_factor). This is a remarkable jump in citations and credit must be given to the editorial team led by our past President Professor Riccardo Audisio (Editor in Chief). 

## _**Network and links with other organisations**_ 

The Association continues to grow its links with other specialties and to re-establish itself as the umbrella organisation for cancer surgeons, including forming membership links with other specialties and setting up partnerships for joint conferences in future. 

Our **BASO Trainees Group** is also proactively expanding its partnership opportunities and has representation on the ASiT Council. BASO Trainees maintains a portfolio of Trainees Prizes of £100 each for the best surgical oncology presentations at the Annual ASiT Conference, and SCTS Annual Meeting held this year. 

## **European Society of Surgical Oncology** 

BASO had signed a ’memorandum-of-understanding’ with our European sister society **ESSO** to strengthen the affiliation between the two societies. BASO members did get affiliate membership to ESSO, however, with the updated agreement, BASO members now enjoy standard membership benefits of ESSO including reduced registration rates to the ESSO Annual conference, courses and training programmes. BASO members also get the opportunity to apply to an international career development programme and access to the membership restricted areas to the ESSO website. BASO individuals will now have the voting right at the ESSO General Assembly. 

## **NIHR’s Clinical Research Network** 

The Association also maintains its relationship with the NIHR’s Clinical Research Network, and supports the ‘Tomorrow’s Leaders’ programme which enrols the future leaders in the field of surgical oncology and research. These leaders are encouraged to join our trainees' membership and are offered support to enhance their career in surgical oncology via short workshops, methodology training, research grant, etc. 

## **National Clinical Guidelines** 

BASO continues to maintain a strong presence when National Clinical Guidelines are either developed or updated. BASO Trustees are appointed as the Specialist Advisors for the NICE’s Interventional Procedure Programmes. Furthermore, BASO Trustees have been contributing to numerous consultations, and are active members of the different Cancer Commissioning Groups. 

## **BASO@ UK Oncology Forum** 

BASO maintains an ongoing collaboration with the UK Oncology Forum and delivers a pan-tumour session every year. This national clinically focussed meeting is open to UK Cancer HCPs. And is free for BASO members to attend. In 2020, BASO hosted the 'BASO updates on multidisciplinary teams **'** session chaired by Mr Hamady, BASO Vice President. BASO Council aims to develop this collaboration further. 

-5- 



## **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE** 

## **TRUSTEES' ANNUAL REPORT (continued)** 

## **YEAR ENDED 30 JUNE 2021** 

## **BASO Symposium @ Association of Surgeons of India Annual Conference** 

BASO delivered a joint BASO-ASI Symposium on ‘ _Extremity Soft Tissue Sarcoma – A Therapeutic Quagmire’_ at the ASI 80[th] Annual conference in December 2020. The conference was a well-received meeting with 6000 delegates in attendance. The session was co-chaired by Mr Anant Desai, BASO Trustee and ASI Panelists, and BASO talks were presented by Mr Andrew Hayes, Consultant Sarcoma Surgeon, and Mr Michael Parry, Orthopaedic Oncologists. 

BASO Council is keen on developing further collaborative sessions at their future meetings 

## **Cancer Services Committee** 

BASO~ACS continues chairing the RCSENG’s **Cancer Services Committee** , and is now invited to offer expert advice towards the ‘Future of Surgery’ Commission, and has contributed on ‘Restructuring of the MDTs’, and GMC’s proposal on Draft Credentialing Frame Work. As a surgical oncology society, we are actively engaged in decision making with organisations such as NICE, NCEPOD, Specialist Cancer CRG, the Royal College of Surgeons, and GMC. 

## **BASO Publications** 

In addition, this accounting year, BASO also engaged with and contributed to: 

- In December 2020, BASO worked with Health Awareness on the 2020 Innovations in Oncology campaign and produced an article on ‘ **Digital surgery in the hand of the surgeon’** . This article was prepared by **Professor Jim Khan,** BASO Trustee and Dr Afsana Elanko, Director of Education. 

- In June 2021, BASO contributed with the article ‘ **Improving early cancer diagnosis with better detection’** on **health Awareness on the 2021 Innovations in Oncology campaign, launched through the Guardian. The article was prepared by Mr Zaed Hamady** BASO Trustee and Dr Afsana Elanko, Director of Education. 

## **BASO Endorsed Meetings** 

This year, BASO endorsed the following events & meetings: 

- Colorectal FRCS viva practice webinar: 21[st] May and 2[nd] July 2021 

- ESSO HPB course: 8-10 Nov 2021 

BASO~ACS continues to support and promote the development of cancer treatment, research, patient care, and education and training of our future generation of oncologists. 

## **Financial Review** 

## _**Membership**_ 

Membership of the Association remains stable during the course of the year.  Membership subscriptions for 2020-21 continued to be kept intentionally low at £180 for full membership as the Association still holds high levels of reserves. 

The subscriptions for the BASO Trainees for 2020-21 is also unchanged. As agreed at the 2017 AGM, BASO offers a 50% discounted fee to the Full Membership of the BASO~ACS for two years to a BASO Trainees member upon completion of training, provided they were the paying member of the Society for two consecutive years. 

-6- 



## **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE** 

## **TRUSTEES' ANNUAL REPORT (continued) YEAR ENDED 30 JUNE 2021** 

## _**EJSO**_ 

The profits from the EJSO are offset against the cost of the membership subscriptions to the EJSO and these are included in the final reconciliation.  A new Journal Publishing agreement between ESSO and BASO as owners, and Elsevier as publishers of the Journal, was made as of 9[th] December 2020. Elsevier paid a oneoff signing bonus of £50,000 to both the Societies that was split 50:50 between BASO and ESSO. 

This new agreement with added benefits and revenues for both the Societies began on 1[st] January 2021 and shall conclude on 31[st] December 2027. All the parties agreed to meet between Sep-Dec 2024 to review the performance of the Journal in light of expectations and overall market conditions. The updated agreement and the EJSO progression will secure the future income stream for BASO. 

The Journal has generated a healthy profit for BASO~ACS in 2020 with an income of £65,367 after the deduction of BASO’s membership subscription for the year.  It is hoped that the EJSO will continue to grow under the editorship of Professor Riccardo A Audisio. 

## _**BASO Grants and Prizes**_ 

**BASO (NIHR) Research Project Grant** The 2020 BASO NIHR Research Project Grant of £3,000 was awarded to the CovidSurg- Cancer Study in April 2020. Two further applications were received in response to the 2020 call for submissions. It was agreed by the NC to merge these applications with the 2021 round of submissions, thereby, allowing trainees to submit their research work for BASO (NIHR) research grant. 

**Ronald Raven Travelling Fellowship Grant** of **£3,000 in total** was awarded to: **Mr Neil Foden** , SPR, Otolaryngology, South London Deanery **Laurence Glancz,** ST8 Neurosurgery Trainee, Nottingham University Hospitals NHS  Trust **BASO Trainees Prize** were awarded at the following external meetings: SCTS Annual Scientific Meeting ASiT Annual Conference 

## _**BASO Annual Meeting 2020**_ 

BASO Trustees strongly feel that the Charity’s continues fulfilling its objective by promoting and sponsoring advancement in research and education of surgical oncology through another successful meeting. The meeting was supported by industry sponsorship and had relatively lower costs. Also, to add to members' benefits, the BASO Council decided to offer the meeting FREE to BASO members. Overall the meeting generated a small profit. 

The conference raised the Association’s presence in the field of Cancer research and has helped engage with various organisations and groups; and offered a great networking platform for the BASO members; recruiting new members. The Association maintains a strong level of reserves and has acquired a new income stream with the EJSO; we can continue to invest our reserves in the promotion of education, training and research via our Annual Conferences. However, we do hope to move towards a cost-neutral financial structure. 

## **Structure, Governance and Management** 

On 1st July 2010 a transfer was made from the unincorporated charity, BASO ~ The Association for Cancer Surgery, to the company limited by guarantee of the same name (Company number: 7225131, Limited by Guarantee and Registered as Charity No 1136067). 

-7- 



## **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE** 

## **TRUSTEES' ANNUAL REPORT (continued)** 

## **YEAR ENDED 30 JUNE 2021** 

The company was incorporated on the 15th April 2010 when new Articles were established. Simultaneous transfers were made to the new Association of Breast Surgery, which is also a company limited by guarantee (Company No 7207053 and Registered as Charity 1135699). 

The two Associations are thus legally independent of each other, with a service agreement between the two Associations to allow for the provision of a shared office and administration.  Whilst the degree of separation has increased over time to allow both Associations to evolve and develop their individual identities, they share many goals and continue to work co-operatively together. 

In May 2020 both the Associations separated their joint database and IT services, and agreed to retain historic records of joint members or those members of ABS who have attended BASO events and vice-versa. The service agreement is subject to periodic review to ensure its continuing relevance and fairness to both Associations.  No further substantive changes are envisaged at this stage. 

The Ordinary Members of the BASO~ACS National Committee (who are also Trustees and Directors) are elected by a ballot of the Membership of the Association, following a ‘Call for Nominations’. Officer posts are notified to the Membership by a call for nominations, followed by a ballot of Trustees if there is more than one candidate.  All Honorary Officers are also Trustees and Directors. All appointments are confirmed by the Membership at the AGM. BASO~ACS has National Committee meetings four times a year. 

BASO also administer the Royal College of Surgeons of England’s Cancer Services Committee, which meets three times a year and is chaired by the President of BASO~ACS. The main business of BASO~ACS is decided upon at its National Committee meetings. Decisions in-between times are made by phone or e-mail communication between the Honorary Officers, with day-to-day issues being dealt with by the Association Manager in liaison with the Honorary Officers.  The Trustees/Directors regularly review the major risks that the charity faces and its reserve policy, combined with an annual internal audit of the controls over key financial systems, which are designed to provide sufficient resources in the event of adverse conditions. No major risks have been identified by the Trustees during the year. 

The Trustees pay due regard to the Charity Commission’s guidance on public benefit when deciding what activities the Charity should undertake. 

## **Reserves Policy** 

BASO ~ ACS holds a sufficient reserve to allow the society to meet financial obligations in the event of a financial loss following an annual conference, to maintain the low level of conference fees for delegates and to obviate the need for increases in Membership fees. The level of reserves, and income from conferences and subscriptions, is crucial to the Association’s work and objectives, and is monitored carefully to ensure a balance between a secure financial position for the Association and minimal costs to Members and potential Members. 

## **Investment Policy** 

The Trustees have power under the Articles to invest funds in the same manner and subject to the same conditions as the Trustees of a trust are permitted to do by the Trustee Act 2000. The Association currently holds its reserves across three deposit accounts:  BASO ~ ACS holds reserves in a Scottish Widows 90-day notice account; an instant access account with Lloyds TSB; and a further instant access account with Virgin Money. BASO Trustees are looking into new investment opportunities for the Association’s reserves. 

-8- 



## **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE** 

## **TRUSTEES' ANNUAL REPORT (continued)** 

## **YEAR ENDED 30 JUNE 2021** 

## **Plans for the Future** 

Growth of the core membership and the breadth of specialisms represented were set out as key aims for 202021. Whilst overall growth has not materialised, membership numbers have remained steady and the Trustees are actively seeking stronger links with other Associations, many of whom have been invited to nominate observers to Council meetings and to whose meetings we have offered to send observers, with the intention of improving communication and understanding in areas of common interest.  Several of these Associations have expressed an interest and the Trustees look forward to reporting on progress in this area in future.  The present Trustees themselves represent a broad cross-section of specialisms and so bring a welcome breadth of experience and perspective to the steering process. 

BASO Trustees intend to establish affiliation support for smaller complex cancer surgical groups, offering them affiliation to BASO membership and endorsement of their meeting, etc., thereby expanding the Association’s distinctive “brand” as the umbrella Society for all Cancer Surgeons. 

To this end, in 2010-21 the Association has made significant contribution to different consultations as organised by NICE. The Trustees are actively developing collaborations with different Royal Colleges, Cancer Commissioning Boards/Reference Groups, Public Health England, GMC and many other interested parties with the aim – as always - of sharing knowledge, opening out debate and improving best practice for the benefit of cancer patients. 

The Cancer Services Committee is currently reviewing the issue of ‘complex surgical oncology training’, ‘Fellowship training recommendations for cancer surgery ‘and ‘MDT revisions & review’. BASO has been invited to contribute to the ‘future of surgery’ commissioning of the RCS; and the CSC would ideally aspire to have direct representation on the RCS Council. The Cancer Services Committee has also been invited to be involved in setting the quality metrics for cancer surgery for the UK, in conjunction with CRUK and NCIN. Mr Hassan Malik, President is representing BASO on this Committee. 

BASO Trustees have joined the Specialised Cancer Clinical Commissioning Group and using its wealth of experts are supporting service development in cancer surgery.  BASO will continue to fund several small grants to support surgical oncology research in partnership with the NIHR. This initiative will foster increasing the breadth of surgical research as well as increasing recruitment of patients into NIHR portfolio studies. 

BASO will broaden its grants and support to regional level meetings, and Student Surgical Societies. BASO Trainees membership is now open to Medical Students and Foundation Year Trainees, those interested in surgical oncology, with the aim to support their training and further education & career in cancer surgery. 

As training and work pressures change with an ever-evolving healthcare service, our BASO Trainees group intends to improve the experience, training, and professional competence of surgical trainees with an interest in oncology, principally in academic and research matters. 

This report has been prepared having taken advantage of the small companies exemption in the Companies Act 2006. 

Approved by the Trustees on 21 November 2021 and signed on their behalf by: 

**Mr John Whiting Honorary Treasurer** 

-9- 



## **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE** 

## **INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES** 

## **YEAR ENDED 30 JUNE 2021** 

I report to the charity trustees on my examination of the accounts of the company for the year ended 30 June 2021 which are set out on pages 11 to 18. 

## **Responsibilities and basis of report** 

As the charity trustees of the company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act'). 

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your company's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act. 

## **Independent examiner's statement** 

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect: 

1.   accounting records were not kept in respect of the company as required by section 386 of the 2006 Act; or 

2.   the accounts do not accord with those records; or 

3.   the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or 

4.   the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). 

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached. 

## **C A Barker FCA** 

Edmund Carr LLP 146 New London Road Chelmsford CM2 0AW 

7 December 2021 

-10- 



## **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE** 

## **STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME AND EXPENDITURE ACCOUNT)** 

## **YEAR ENDED 30 JUNE 2021** 

|**Note**<br>**£**<br>**£**<br>**INCOME from:**<br>Charitable activities:<br>Members' subscriptions<br>32,836<br>-<br>Scientific conference<br>**2**<br>4,110<br>-<br>Publications - EJSO<br>101,547<br>-<br>Other trading activities<br>47<br>-<br>Investments<br>**3**<br>195<br>4<br>**TOTAL INCOME**<br>138,735<br>4<br>**EXPENDITURE on:**<br>Charitable activities<br>Subscriptions - ESSO<br>7,366<br>-<br>Scientific conference<br>**2**<br>3,188<br>-<br>Publications - EJSO<br>11,180<br>-<br>Fellowships & awards<br>**4**<br>500<br>4,000<br>National Committee and support costs<br>**5**<br>53,331<br>-<br>**TOTAL EXPENDITURE**<br>75,565<br>4,000<br>**NET INCOME/(EXPENDITURE)**<br>63,170<br>(3,996)<br>Transfers between funds<br>(2,500)<br>2,500<br>**NET MOVEMENT IN FUNDS**<br>60,670<br>(1,496)<br>**RECONCILIATION OF FUNDS**<br>Total funds brought forward<br>194,062<br>34,951<br>Total funds carried forward<br>254,732<br>33,455<br>**Unrestricted**<br>**Funds**<br>**Funds**<br>**Restricted**|**Note**<br>**£**<br>**£**<br>**INCOME from:**<br>Charitable activities:<br>Members' subscriptions<br>32,836<br>-<br>Scientific conference<br>**2**<br>4,110<br>-<br>Publications - EJSO<br>101,547<br>-<br>Other trading activities<br>47<br>-<br>Investments<br>**3**<br>195<br>4<br>**TOTAL INCOME**<br>138,735<br>4<br>**EXPENDITURE on:**<br>Charitable activities<br>Subscriptions - ESSO<br>7,366<br>-<br>Scientific conference<br>**2**<br>3,188<br>-<br>Publications - EJSO<br>11,180<br>-<br>Fellowships & awards<br>**4**<br>500<br>4,000<br>National Committee and support costs<br>**5**<br>53,331<br>-<br>**TOTAL EXPENDITURE**<br>75,565<br>4,000<br>**NET INCOME/(EXPENDITURE)**<br>63,170<br>(3,996)<br>Transfers between funds<br>(2,500)<br>2,500<br>**NET MOVEMENT IN FUNDS**<br>60,670<br>(1,496)<br>**RECONCILIATION OF FUNDS**<br>Total funds brought forward<br>194,062<br>34,951<br>Total funds carried forward<br>254,732<br>33,455<br>**Unrestricted**<br>**Funds**<br>**Funds**<br>**Restricted**|**Total Funds**<br>**2021**<br>**£**<br>32,836<br>4,110<br>101,547<br>47<br>199|**Total Funds**<br>**2020**<br>£<br>33,922<br>26,945<br>60,234<br>400<br>947|
|---|---|---|---|
||4|138,739|122,448|
||-<br>-<br>-<br>4,000<br>-|7,366<br>3,188<br>11,180<br>4,500<br>53,331|6,445<br>53,308<br>11,701<br>14,010<br>79,990|
||4,000|79,565|165,454|
||(3,996)<br>2,500<br>(1,496)<br>34,951|59,174<br>-<br>-<br>229,013|(43,006)<br>-<br>(43,006)<br>272,019|
||33,455|288,187|229,013|



The charity has no recognised gains or losses other than the results for the period as set out above. 

**The notes on pages 13 to 18 form part of these financial statements.** 

-11- 



## **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE** 

## **BALANCE SHEET AS AT 30 JUNE 2021** 

|**Note**<br>**FIXED ASSETS**<br>Tangible assets<br>**10**<br>**CURRENT ASSETS**<br>Debtors<br>**11**<br>Cash at bank<br>**CREDITORS: Amounts falling due**<br>**within one year**<br>**12**<br>**NET CURRENT ASSETS**<br>**TOTAL ASSETS LESS CURRENT LIABILITIES**<br>**NET ASSETS**<br>**FUNDS**<br>Unrestricted<br>**13**<br>Restricted<br>**14**<br>**TOTAL FUNDS**|**£**<br>**£**<br>704<br>11,188<br>340,605<br>351,793<br>(64,310)<br>287,483<br>288,187<br>288,187<br>254,732<br>33,455<br>288,187<br>**2021**|**£**<br>**£**<br>494<br>5,157<br>265,367<br>270,524<br>(42,005)<br>228,519<br>229,013<br>229,013<br>194,062<br>34,951<br>229,013<br>**2020**|**£**<br>**£**<br>494<br>5,157<br>265,367<br>270,524<br>(42,005)<br>228,519<br>229,013<br>229,013<br>194,062<br>34,951<br>229,013<br>**2020**|
|---|---|---|---|
||||229,013|
||||229,013|
||||194,062<br>34,951|
||||229,013|



For the year ending 30 June 2021 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. 

Directors' responsibilities: 

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; 

- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts. 

These financial statements have been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006 and with the Financial Reporting Standard (FRS102) (effective 1 January 2019). 

These financial statements were approved by the Trustees on 21 November 2021 and are signed on their behalf by: 

## **MR HASSAN MALIK** 

## **MR JOHN WHITING** 

Company Registration Number: 7225131 

**The notes on pages 13 to 18 form part of these financial statements.** 

-12- 



## **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE** 

## **NOTES TO THE FINANCIAL STATEMENTS** 

## **YEAR ENDED 30 JUNE 2021** 

## **1. ACCOUNTING POLICIES** 

## **Basis of accounting** 

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Effective 1 January 2019) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006. 

BASO - The Association for Cancer Surgery meets the definition of a public benefit entity under FRS102.  Assets and Liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.  The financial statements are prepared in sterling, which is the functional currency of the charity, and rounded to the nearest £.  The charity is a company limited by guarantee. 

## **Going Concern** 

The Trustees have considered the impact of the Covid-19 pandemic in their assessment of the charity’s ability to prepare accounts as a going concern. It is difficult to predict the impact on the charity and its funders, but having taken all the factors into account, the Trustees are of the opinion that the charity has sufficient resources to continue trading for the next 12 months from the date of signing these accounts. 

## **Incoming Resources** 

Income from conferences held during the year is accounted for on an accruals basis. Membership subscriptions are recognised on receipt. 

## **Resources Expended** 

All expenditure is accounted for on an accruals basis and includes VAT as the charity is not VAT registered. The majority of costs are attributable to specific charitable activities (ie conferences/awards).  Fellowships and awards are accounted for in the period in which they are notified to the recipient. Governance costs are associated with the governance arrangements of the charity. Staff and office costs are recharged to the charity under the service agreement with ABS. 

## **Debtors and creditors** 

Trade and other debtors are recognised at the settlement amount due. Creditors are recognised at their settlement amount. 

## **Cash and cash equivalents** 

Cash and cash equivalents comprise cash on hand and deposits. 

## **Fixed Assets and Depreciation** 

Fixed assets are shown at historical cost. Expenditure on tangible fixed assets is capitalised. The cost of other items is written off as incurred. 

Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful economic life of that asset as follows: 

Computer equipment 25% reducing balance Fixtures  & fittings        25% reducing balance 

-13- 



## **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMENTS** 

## **YEAR ENDED 30 JUNE 2021** 

## **ACCOUNTING POLICIES continued** 

## **Fund accounting** 

Funds held by the charity are either: 

Unrestricted general funds – these are funds which can be used in accordance with the   charitable objects at the discretion of the trustees. 

Designated funds – these are funds set aside by the trustees out of unrestricted funds for specific future purposes or projects. 

Restricted funds – these are funds that can only be used for particular restricted purposes within the objects of the charity. 

## **2. CHARITABLE ACTIVITIES SCIENTIFIC CONFERENCE** 

|**Income**<br>Fees<br>Lecture grants<br>**Expenditure**<br>Speaker expenses<br>Venue and catering costs<br>Other conference costs|**Unrestricted**<br>**Funds**<br>**£**<br>4,110<br>-<br>4,110<br>-<br>-<br>3,188<br>3,188|**Restricted**<br>**Funds**<br>**£**<br>-<br>-<br>-<br>-<br>-<br>-<br>-|**Total Funds**<br>**2021**<br>**£**<br>4,110<br>-<br>4,110<br>-<br>-<br>3,188<br>3,188|**Total Funds**<br>**2020**<br>**£**<br>25,945<br>1,000|
|---|---|---|---|---|
|||||26,945|
|||||6,172<br>32,022<br>15,114|
|||||53,308|



All conference income and expenditure in 2020 was unrestricted. 

## **3. INVESTMENT INCOME** 

All of the charity's investment income arises from interest bearing deposit accounts. 

## **4. FELLOWSHIPS & AWARDS** 

|Ronald Raven Prize<br>Ronald Raven Travel Scholarships<br>Alan Edwards Memorial Fund<br>Other Awards|**Unrestricted**<br>**Funds**<br>**£**<br>-<br>-<br>-<br>500<br>500|**Restricted**<br>**Funds**<br>**£**<br>600<br>3,000<br>400<br>-<br>4,000|**Total Funds**<br>**2021**<br>**£**<br>600<br>3,000<br>400<br>500<br>4,500|**Total Funds**<br>**2020**<br>**£**<br>600<br>3,000<br>400<br>10,010|
|---|---|---|---|---|
|||||14,010|



In 2020 Other Awards were paid from unrestricted funds. All other prizes were paid from restricted funds. 

-14- 



## **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE** 

## **NOTES TO THE FINANCIAL STATEMENTS** 

## **YEAR ENDED 30 JUNE 2021** 

## **5. NATIONAL COMMITTEE & SUPPORT COSTS** 

|Staff salaries and pension costs<br>SOTA committee & meeting costs<br>Other support costs<br>Governance costs (note 6)<br>National committee costs<br>Service agreement charges|**Unrestricted**<br>**Funds**<br>**£**<br>40,272<br>-<br>1,800<br>-<br>5,344<br>5,915<br>53,331|**Restricted**<br>**Funds**<br>**£**<br>-<br>-<br>-<br>-<br>-<br>-<br>-|**Total Funds**<br>**2021**<br>**£**<br>40,272<br>-<br>1,800<br>-<br>5,344<br>5,915<br>53,331|**Total Funds**<br>**2020**<br>**£**<br>41,501<br>9,207<br>11,248<br>1,731<br>7,436<br>8,867|
|---|---|---|---|---|
|||||79,990|



All national committee and support costs in 2020 were unrestricted. 

## **6. GOVERNANCE COSTS** 

|Accounting and payroll services<br>Independent examination fee<br>Fees payable to independent examiner<br>Bank charges<br>Other professional fees<br>**7. STAFF COSTS AND EMOLUMENTS**|**Unrestricted**<br>**Funds**<br>**£**<br>4,025<br>575<br>4,600<br>416<br>899<br>5,915|**Restricted**<br>**Funds**<br>**£**<br>-<br>-<br>-<br>-<br>-<br>-|**Total Funds**<br>**2021**<br>**£**<br>4,025<br>575<br>4,600<br>416<br>899<br>5,915|**Total Funds**<br>**2020**<br>**£**<br>3,871<br>575|
|---|---|---|---|---|
|||||4,446<br>438<br>3,983|
|||||8,867|
||||||



|**Total staff costs were as follows:**<br>Wages & salaries<br>Pension costs (defined contribution scheme)|**2021**<br>**£**<br>37,072<br>3,200<br>40,272|**2020**<br>**£**<br>38,301<br>3,200|
|---|---|---|
|||41,501|



## _**Particulars of employees:**_ 

The average number of employees during the year was 1, (full-time equivalent - 0.8) (2020 - 1 employee and 0.8 FTE) 

No employee received remuneration of more than £60,000 during the period. 

-15- 



## **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMENTS** 

## **YEAR ENDED 30 JUNE 2021** 

## **8. NET OUTGOING RESOURCES FOR THE YEAR** 

||**2021**|**2020**|
|---|---|---|
|This is stated after charging:|**£**|**£**|
|Depreciation|168|167|



## **9. TRUSTEES' REMUNERATION** 

None of the Trustees were paid any remuneration by the Association during the period. Trustees are reimbursed reasonable expenses incurred when acting on behalf of the company. Expenses totalling £188 were reimbursed to 1 trustee during the period (2020 - £4,015 to 9 Trustees). 

## **10. TANGIBLE FIXED ASSETS** 

|**COST**<br>At 1 July 2020<br>Additions<br>Disposals<br>**At 30 June 2021**<br>**DEPRECIATION**<br>At 1 July 2020<br>Charge for the year<br>**At 30 June 2021**<br>**NET BOOK VALUE**<br>**At 30 June 2021**<br>At 30 June 2020<br>**11. DEBTORS**<br>Prepayments<br>Other Debtors|**Computer**<br>**equipment**<br>**£**<br>2,682<br>378<br>-<br>3,060<br>2,221<br>154|**Fixtures**<br>**& fittings**<br>**£**<br>2,421<br>-<br>-<br>2,421<br>2,388<br>14|**Total**<br>**£**<br>5,103<br>378<br>-|
|---|---|---|---|
||||5,481|
||||4,609<br>168|
||2,375|2,402|4,777|
||685<br>461|19<br>33<br>**2021**<br>**£**<br>1,162<br>10,026<br>11,188|704|
||||494|
||||**2020**<br>**£**<br>-<br>5,157|
||||5,157|



-16- 



## **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE** 

## **NOTES TO THE FINANCIAL STATEMENTS** 

## **YEAR ENDED 30 JUNE 2021** 

## **12. CREDITORS: Amounts falling due within one year** 

|Trade creditors<br>Other creditors<br>Accruals<br>Deferred income|**2021**<br>**£**<br>-<br>-<br>8,985<br>55,325<br>64,310|**2020**<br>**£**<br>1,674<br>125<br>5,791<br>34,415|
|---|---|---|
|||42,005|



Deferred income relates to EJSO royalties received in advance for the following period. 

## **13. UNRESTRICTED FUNDS** 

|**13. UNRESTRICTED FUNDS**|||||
|---|---|---|---|---|
|**Current year**<br>**Balance at**<br>**01/07/2020**<br>£<br>General unrestricted funds<br>194,062<br>**_Prior year_**<br>**_Balance at_**<br>**_01/07/2019_**<br>_£_<br>_General unrestricted funds_<br>_233,138_<br>**14. RESTRICTED FUNDS**<br>**Current year**<br>**Balance at**<br>**01/07/2020**<br>£<br>a)<br>Alan Edwards Memorial Fund<br>5,968<br>b)<br>Ronald Raven Prize Fund<br>569<br>c)<br>Ronald Raven Travelling<br>28,414<br>Fellowship Fund<br>34,951|**Balance at**<br>**01/07/2020**<br>£<br>194,062|**Incoming**<br>**Outgoing**<br>**£**<br>**£**<br>138,735<br>(75,565)<br>**_Incoming_**<br>**_Outgoing_**<br>**_£_**<br>**_£_**<br>_122,378_<br>_(161,454)_<br>**Incoming**<br>**Outgoing**<br>**£**<br>**£**<br>1<br>(400)<br>-<br>(600)<br>3<br>(3,000)<br>4<br>(4,000)<br>**Movement in resou**<br>**Movement in resou**|**Transfers**<br>**£**<br>(2,500)<br>**_Transfers_**<br>**_£_**<br>_-_<br>**Transfers**<br>**£**<br>-<br>2,500<br>-<br>2,500<br>**rces:**<br>**rces:**|**Balance at**<br>**30/06/2021**<br>**£**<br>254,732|
||**_Balance at_**<br>**_01/07/2019_**<br>_£_<br>_233,138_|||**_Balance at_**<br>**_30/06/2020_**<br>**_£_**<br>_194,062_|
|||||**Balance at**<br>**30/06/2021**<br>**£**<br>5,569<br>2,469<br>25,417|
||34,951|||33,455|



-17- 



## **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 30 JUNE 2021** 

## **14. RESTRICTED FUNDS** 

|**_Prior year_**<br>a)<br>_Alan Edwards Memorial Fund_<br>b)<br>_Ronald Raven Prize Fund_<br>c)<br>_Ronald Raven Travelling_<br>_Fellowship Fund_|**_Balance at_**<br>**_01/07/2019_**<br>_£_<br>_6,357_<br>_1,163_<br>_31,361_<br>_38,881_|**_Movement in resources:_**<br>**_Incoming_**<br>**_Outgoing_**<br>**_£_**<br>**_£_**<br>_11_<br>_(400)_<br>_6_<br>_(600)_<br>_53_<br>_(3,000)_<br>_70_<br>_(4,000)_|**_Movement in resources:_**<br>**_Incoming_**<br>**_Outgoing_**<br>**_£_**<br>**_£_**<br>_11_<br>_(400)_<br>_6_<br>_(600)_<br>_53_<br>_(3,000)_<br>_70_<br>_(4,000)_|**_Transfers_**<br>**_£_**<br>_-_<br>_-_<br>_-_<br>_-_|**_Balance at_**<br>**_30/06/2020_**<br>**_£_**<br>_5,968_<br>_569_<br>_28,414_|
|---|---|---|---|---|---|
|||_70_|_(4,000)_||_34,951_|



## **15. ANALYSIS OF NET ASSETS (between restricted and unrestricted funds)** 

|**Current year**<br>Restricted funds<br>Unrestricted funds<br>**_Prior year_**<br>_Restricted funds_<br>_Unrestricted funds_|**Tangible**<br>**fixed assets**<br>**£**<br>-<br>704|**Other net**<br>**assets**<br>**£**<br>33,455<br>254,028<br>287,483<br>**_Other net_**<br>**_assets_**<br>**_£_**<br>_34,951_<br>_193,568_<br>_228,519_|**Total**<br>**£**<br>33,455<br>254,732|
|---|---|---|---|
||704||288,187|
||**_Tangible_**<br>**_fixed assets_**<br>**_£_**<br>_-_<br>_494_||**_Total_**<br>**_£_**<br>_34,951_<br>_194,062_|
||_494_||_229,013_|



## **16. COMPANY LIMITED BY GUARANTEE** 

The company is controlled by its members. Every member of the company undertakes to contribute to the assets of the Company in the event of the same being wound up during the time he/she is a member, or within one year afterwards, for the payments of the debts and liabilities of the company contracted before the time at which he/she ceases to be a member and of the costs, charges and expenses of winding up the same, and for the adjustments of the rights of the contributors among themselves such amount as may be required not exceeding one pound. 

## **17. RELATED PARTY TRANSACTIONS** 

There were no related party transactions that require disclosure during the year other than the reimbursement of expenses to Trustees, disclosed in Note 9. 

-18-